Evidence map›Paper›PMID 37328688›Full record

ArticleScientific reports2023

Applying in-situ visible photopolymerization for fabrication of electrospun nanofibrous carrier for meloxicam delivery.

Z Ahmadipour, M S Seyed Dorraji, H R Ashjari, F Dodangeh, M H Rasoulifard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Z AhmadipourApplied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.
M S Seyed DorrajiApplied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran. dorraji@znu.ac.ir.
H R AshjariApplied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.
F DodangehApplied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.
M H RasoulifardApplied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.
University of Zanjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite meloxicam's many benefits, it will cause many drawbacks if the meloxicam release rate is not controlled. Accordingly, we introduced a technique based on the electrospinning process to control the release rate and also to reduce side effects. For this purpose, different nanofibers were used as drug couriers. Nanofibers were prepared using polyurethane, polyethylene glycol, and light curable poly (ethylene glycol) diacrylate (PEGDA) by electrospinning. In fact, light curable poly (ethylene glycol) diacrylate (PEGDA) was synthesized as a hydrophilic functional group. Next, PEGDA and polyurethane were used simultaneously to fabricate the drug carrier nanofiber in a single processing step, and the electrospinning apparatus was equipped with a blue light source for in-situ photopolymerization during the electrospinning process. The molecular structures of nanofibers and PEGDA were investigated by FT-IR,

Indexed as

NanofibersDrug CarriersMeloxicamPolyethylene GlycolsPolyurethanesSpectroscopy, Fourier Transform InfraredDrug CarriersMeloxicampoly(ethylene glycol)diacrylatePolyethylene GlycolsPolyurethanes

Identifiers

PMID37328688
PMCPMC10275867
OpenAlexW4380989278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.